Back to top
more

Integer Holdings (ITGR)

(Real Time Quote from BATS)

$107.15 USD

107.15
65,819

+0.63 (0.59%)

Updated Aug 4, 2025 01:06 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value C Growth D Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 36% (158 out of 246)

Industry: Medical - Instruments

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Baxter Stock up on Launch of Disposable Curved Applicator

by Zacks Equity Research

Baxter's (BAX) wide array of surgical products see lucrative market prospects.

Nitish Marwah headshot

New Strong Buy Stocks for December 19th

by Nitish Marwah

Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List today:

Zacks Equity Research

GNC Holdings Global Business Strong, Same Store Sales Weak

by Zacks Equity Research

GNC Holdings' (GNC) domestic franchise revenues worsen due to soft retail same store sales and fewer franchise stores.

Zacks Equity Research

Here's Why You Should Hold Cooper Companies (COO) Stock Now

by Zacks Equity Research

Cooper Companies' (COO) strong CVI segment favors the stock while a soft Fertility unit raises concern.

Zacks Equity Research

Here's Why You Should Buy Haemonetics (HAE) Stock Right Now

by Zacks Equity Research

Haemonetics (HAE) continues to witness strong growth in Plasma franchise.

Zacks Equity Research

CONMED's Buffalo Filter Buyout Likely to be Accretive in 2020

by Zacks Equity Research

CONMED's (CNMD) comprehensive surgical smoke evacuation portfolio lends it a competitive edge in the industry.

Zacks Equity Research

Zacks.com featured highlights include: Verint Systems, Integer, AMN Healthcare Services, Xilinx and United States Cellular

by Zacks Equity Research

Zacks.com featured highlights include: Verint Systems, Integer, AMN Healthcare Services, Xilinx and United States Cellular

Zacks Equity Research

Hologic's (HOLX) New Offering to Revitalize Cynosure Division

by Zacks Equity Research

The latest launch along with certain new developments is expected to boost top-line contribution from Hologic's (HOLX) Cynosure division in the near term.

Nitish Marwah headshot

New Strong Buy Stocks for December 14th

by Nitish Marwah

Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List today:

Zacks Equity Research

Bruker Profits from NANO & CALID, New Buyout Holds Promise

by Zacks Equity Research

Bruker (BRKR) looks to gain from high demand for ADVANCE X-ray and nano-analysis products. The CALID Group also raises hope with high-single digit robust year-to-date revenues.

Zacks Equity Research

Thermo Fisher (TMO) Rides on New Buyouts and APAC Strength

by Zacks Equity Research

We are upbeat about Thermo Fisher's (TMO) recent buyout of Advanced Bioprocessing business, which will add complementary cell culture products to the company's bioproduction suit.

Zacks Equity Research

5 Stocks Trading Near 52-Week High with More Room to Run

by Zacks Equity Research

Investors target stocks that have been on a bullish run lately. Stocks seeing price strength have a high chance of carrying the momentum forward.

Zacks Equity Research

Varian Medical's Eclipse Picked by Paul Scherrer Institute

by Zacks Equity Research

Varian Medical's (VAR) latest developments fortify its foothold in the global cancer therapeutics market.

Zacks Equity Research

Here's Why You Should Hold Baxter International (BAX) Now

by Zacks Equity Research

Baxter's (BAX) recent string of developments boost the stock while segmental softness is a concern.

Zacks Equity Research

Edwards Lifesciences Advances in AI With Bay Labs Tie-Up

by Zacks Equity Research

Through the tie-up, Edwards Lifesciences (EW) aims at improving detection of heart diseases and enhancing quality by using Bay Labs' ability to apply AI to cardiovascular imaging.

Zacks Equity Research

CVS Health Aetna Synergy Impressive, PBM Selling Season Solid

by Zacks Equity Research

CVS Health (CVS) estimates a $750-million earning from near-term synergies with low- to mid-single digit addition in the second year after the closure of Aetna transaction.

Zacks Equity Research

STERIS Rides on Favorable Industry Trends, Rivalry a Concern

by Zacks Equity Research

STERIS (STE) is currently displaying strong top-line growth on encouraging market trends along with a new product and service portfolio.

Zacks Equity Research

NuVasive's Monolith Corpectomy System Ok'd for Expanded Use

by Zacks Equity Research

NuVasive's (NUVA) latest FDA 510 (k) clearance receipt is expected to augment customer base and market reach.

Zacks Equity Research

Hologic Unveils Omni Hysteroscope, Boosts GYN Surgical Arm

by Zacks Equity Research

Hologic (HOLX) highlights that a direct visualization of the uterine cavity in women with abnormal uterine bleeding will set a benchmark for the medical test.

Zacks Equity Research

Hill-Rom Adds New Capabilities to Centrella Smart+ Beds

by Zacks Equity Research

Hill-Rom (HRC) stays focused on expansion through product development. The latest move is expected to boost the top-line results of the company.

Zacks Equity Research

Varian Medical ProBeam-Equipped Emory Center Opens in Georgia

by Zacks Equity Research

Varian Medical's (VAR) flagship ProBeam system has lucrative prospects.

Zacks Equity Research

Here's Why You Should Buy Myriad Genetics (MYGN) Stock Now

by Zacks Equity Research

Myriad Genetics (MYGN) see strong testing volumes from new products.

Zacks Equity Research

Insulet Gains on Omnipod Reimbursement Update, Rivalry Stiff

by Zacks Equity Research

Insulet Corporation (PODD) continues to expand Omnipod's market access on growing reimbursements. The company operates in a highly competitive environment.

Zacks Equity Research

Baxter & EFCNI Collaborate to Improve Care for Preterm Born

by Zacks Equity Research

Baxter's (BAX) latest move is likely to increase the use of Baxter's Numeta G13E triple-chamber PN product.

Zacks Equity Research

Myriad Genetics Announces Encouraging EndoPredict Test Data

by Zacks Equity Research

Myriad Genetics (MYGN) forges ahead with initiatives to boost the adoption of the EndoPredict tests.